• Text size
  • Normal
  • Big

Company History

January 2016:A license agreement signed with Athersys, Inc. for the development and commercialization of novel cell therapy treatments, including MultiStem® for the treatment of ischemic stroke in Japan.
October 2015:Opening of Yokohama laboratory  in Yokohama City University Advanced Medical Research Center
June 2015:Listed on the Tokyo Stock Exchange market Mothers (code: 4593).
October 2014:Start of collaborative research with Yokohama City University on cellular and tissue-based products using iPS and other cells.
September 2014:Main office was moved to Minato-ku, Tokyo.
February 2014:Sighregen Co.,Ltd.., a joint venture company with Sumitomo Dainippon Pharma Co., Ltd., was established.
December 2013:Agreement signed with Sumitomo Dainippon Pharma Co., Ltd. on the joint development in Japan of iPS cell–derived RPE cells for the treatment of age-related macular degeneration. A patent licensing agreement and a joint venture contract was also signed.
Ophthalmic viscoelastic preparation business was transferred from Aqumen Biopharmaceuticals K.K.
October 2013:Opening of our laboratory (currently the Kobe Research Institute) in Chuo-ku, Kobe.
September 2013:Business name was changed to HEALIOS K.K.
The Tokyo office and the main office were moved to Chuo-ku, Tokyo.
March 2013:A patent licensing agreement was concluded with RIKEN, on RPE cells for the treatment of age-related macular degeneration.
February 2013:A patent licensing agreement was concluded with iPS Academia Japan, Inc. on iPS cell basic technology related to cellular therapy products containing RPE cells as an active ingredient.
December 2012:Tokyo office was opened in Chiyoda-ku, Tokyo.
August 2011:Healios joins the Riken Venture system.
February 2011:Retina Institute Japan, K.K. (currently HEALIOS K.K.) was established in Higashi-ku, Fukuoka City.
Discussions were initiated on strategies to commercialize RPE cell transplantation as a treatment for age-related macular degeneration.